While you may think of healthcare as only covering human health, animal and pet health is also a growing sector. Click to ...

Strategies that practices can implement to prevent veterinary burnout were discussed during a session at the 2024 Fetch ...

The vaccine is expected to be available at veterinary clinics and hospitals nationwide this fall. NOBIVAC NXT FeLV is the first and only feline leukemia virus vaccine built on Merck Animal Health ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

is set to be available in veterinary clinics and hospitals across the United States this fall. NOBIVAC NXT FeLV is the first FeLV vaccine leveraging Merck's RNA-particle platform, similar to the ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close. Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog ...